Lv1
40 积分 2025-03-28 加入
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
3小时前
已完结
Exercise against nonsmall-cell lung carcinoma: novel insights
4小时前
求助中
Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: A comprehensive analysis of plasma proteomics and therapeutic implications
9天前
已完结
Exercise against nonsmall-cell lung carcinoma: Novel insights
9天前
已关闭
A single-cell atlas reveals immune heterogeneity in anti-PD-1-treated non-small cell lung cancer
19天前
已完结
Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer
19天前
已完结
[A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage ⅢA EGFR-mutant lung adenocarcinoma]
1个月前
已完结
Targeted Therapies, Biologics, and Immunotherapy in the Neoadjuvant and Adjuvant Settings: Perioperative Risks
1个月前
已完结
Enhancing PD-1 blockade in NSCLC: Reprogramming tumor immune microenvironment with albumin-bound statins targeting lipid rafts and mitochondrial respiration
1个月前
已完结
A multi-center phase II randomized study of CustOmized neoadjuvant ThErapy vs standard chemoTherapy in non-small cell lung cancer (NSCLC) patients with resectable stage IIIA (N2) disease
1个月前
已关闭
皖公网安备34019202002308
